Sanofi-Aventis Administrative Office
Istanbul, Turkey (Türkiye)
NCT Number: NCT00343239
Study objectives:
To determine Ro resection rate of Docetaxel, cisplatin and fluorouracil combination for the treatment of neoadjuvant gastric carcinoma.
Looking for future studies?
Notify Me18 year–70 year
All sexes
Interventional
Phase 2
Istanbul, Turkey (Türkiye)
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Formulation: infusion solution
Route of administration: IV infusion on the first day of each 21-day cycle
Dose regimen: 75 mg/m2
Formulation: infusion solution
Route of administration: IV infusion on the first day of each 21-day cycle
Dose regimen: 75 mg/m2
Formulation: infusion solution
Route of administration: IV infusion on the first day of each 21-day cycle
Dose regimen: 750 mg/m2/day for 5 days
Time frame: 3 cycles
Sanofi
Industry
Docetaxel, Cisplatin and Fluorouracil Combination in the Neoadjuvant Treatment of Locally Advanced Gastric Adenocarcinoma : Phase II Clinical Study
Acronym: NEOTAX
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07682220
Behavior, Digestive System Diseases
Harbin, Heilongjiang, China
View Trial DetailsNCT05334719
Digestive System Diseases, Digestive System Neoplasms
Minato-ku, Tokyo, Japan
View Trial DetailsNCT03030404
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT03675737
Digestive System Diseases, Digestive System Neoplasms
Los Angeles, California, United States
View Trial Details